BG107482A - Лекарствено средство за имунотерапия на злокачествени тумори - Google Patents

Лекарствено средство за имунотерапия на злокачествени тумори Download PDF

Info

Publication number
BG107482A
BG107482A BG107482A BG10748203A BG107482A BG 107482 A BG107482 A BG 107482A BG 107482 A BG107482 A BG 107482A BG 10748203 A BG10748203 A BG 10748203A BG 107482 A BG107482 A BG 107482A
Authority
BG
Bulgaria
Prior art keywords
tumor
dendritic cells
cells
cell suspension
induced
Prior art date
Application number
BG107482A
Other languages
Bulgarian (bg)
English (en)
Inventor
Claudia Ulbrich
Klaus-Dieter Rockensuss
Armin Grossmann
Original Assignee
Liponova Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liponova Gmbh filed Critical Liponova Gmbh
Publication of BG107482A publication Critical patent/BG107482A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BG107482A 2000-07-28 2003-01-21 Лекарствено средство за имунотерапия на злокачествени тумори BG107482A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116362 2000-07-28
PCT/EP2001/008455 WO2002009745A1 (de) 2000-07-28 2001-07-21 Arzneimittel zur immuntherapie maligner tumoren

Publications (1)

Publication Number Publication Date
BG107482A true BG107482A (bg) 2003-11-28

Family

ID=8169380

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107482A BG107482A (bg) 2000-07-28 2003-01-21 Лекарствено средство за имунотерапия на злокачествени тумори

Country Status (19)

Country Link
US (2) US20030129206A1 (cs)
EP (1) EP1305041B1 (cs)
JP (1) JP2004505058A (cs)
AT (1) ATE330626T1 (cs)
AU (1) AU2001279775A1 (cs)
BG (1) BG107482A (cs)
CA (1) CA2417374A1 (cs)
CY (1) CY1105179T1 (cs)
CZ (1) CZ299669B6 (cs)
DE (1) DE50110274D1 (cs)
DK (1) DK1305041T3 (cs)
ES (1) ES2267800T3 (cs)
HU (1) HUP0300772A3 (cs)
NO (1) NO20030420L (cs)
PL (1) PL358675A1 (cs)
PT (1) PT1305041E (cs)
SI (1) SI1305041T1 (cs)
SK (1) SK822003A3 (cs)
WO (1) WO2002009745A1 (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211971A1 (en) * 2001-09-17 2003-11-13 Srivastava Pramod K. Compositions and methods for prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with compositions comprising unfractionated cellular proteins
CA2514500A1 (en) * 2003-02-20 2004-09-10 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
MY160857A (en) 2006-02-03 2017-03-31 Malaysian Palm Oil Board A cancer vaccine
EP1974742A1 (en) * 2007-03-29 2008-10-01 LipoNova AG A method for improving the manufacturing process of a tumour vaccine
KR20120081972A (ko) 2009-07-02 2012-07-20 아이티에이치 임뮨 세라피 홀딩스 에이비 엑소좀에 기초한 암의 치료
CN105807053B (zh) 2016-04-15 2019-04-02 苏州药明康德新药开发股份有限公司 一种肿瘤解离试剂在流式细胞检测中的应用
ES2908885T3 (es) 2017-07-05 2022-05-04 Vcc Medical Deutschland Gmbh Método para fabricar una vacuna tumoral

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
DE19633731A1 (de) * 1996-08-21 1998-02-26 Johann Hinrich Prof Dr Peters Hybridzellen zur Steigerung der Immunogenität von Tumorzellen
AU2872199A (en) * 1998-02-20 1999-09-06 Rockefeller University, The Apoptotic cell-mediated antigen presentation to dendritic cells
DE19812004A1 (de) * 1998-03-19 1999-09-30 Forschungszentrum Juelich Gmbh Dehydrogenasen mit verbesserter NAD-Abhängigkeit, deren Herstellung und Verwendung
JP2002506886A (ja) * 1998-03-20 2002-03-05 ジェンザイム・コーポレーション 抗腫瘍免疫亢進
DE69939821D1 (de) * 1998-04-02 2008-12-11 Univ California Zusammensetzungen zur erhöhung der zahl antigen präsentierender zellen und der antitumoralen antwort in menschlichen patienten
US6045990A (en) * 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature

Also Published As

Publication number Publication date
SK822003A3 (en) 2004-05-04
HUP0300772A2 (en) 2003-08-28
HUP0300772A3 (en) 2005-11-28
CZ299669B6 (cs) 2008-10-08
CZ2003179A3 (cs) 2004-01-14
SI1305041T1 (sl) 2006-12-31
CY1105179T1 (el) 2010-03-03
US20030129206A1 (en) 2003-07-10
HK1055562A1 (zh) 2004-01-16
DE50110274D1 (de) 2006-08-03
NO20030420D0 (no) 2003-01-27
WO2002009745A1 (de) 2002-02-07
EP1305041B1 (de) 2006-06-21
JP2004505058A (ja) 2004-02-19
CA2417374A1 (en) 2003-01-27
ES2267800T3 (es) 2007-03-16
US20070134275A1 (en) 2007-06-14
DK1305041T3 (da) 2006-10-23
PL358675A1 (en) 2004-08-09
AU2001279775A1 (en) 2002-02-13
EP1305041A1 (de) 2003-05-02
PT1305041E (pt) 2006-09-29
NO20030420L (no) 2003-01-27
ATE330626T1 (de) 2006-07-15

Similar Documents

Publication Publication Date Title
JP5986196B2 (ja) 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法
AU2008303453B2 (en) An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
US20080213895A1 (en) Method for culturing dendritic cells (DC) and cytokine-induced killer cells (D-CIK) and applications thereof
JP2005515781A (ja) 機能樹状細胞への単球の分化を誘導するための方法およびかかる樹状細胞を含む免疫療法組成物
Liu et al. Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects
JP6235085B2 (ja) 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法
CN108642013A (zh) 一种从脐带血中分离cd34造血干细胞扩大培养后大规模诱导制备树突状细胞方法
CN106943432B (zh) 一种脐带间充质干细胞来源的外泌体及其在制备治疗肝癌药物中的应用
EP1078043A1 (en) New apoptotic bodies, monocyte derived cells containing the same, a process for their preparation and their uses as vaccines
CN111117964A (zh) 一种肿瘤来源外泌体及其制备方法和用途
BG107482A (bg) Лекарствено средство за имунотерапия на злокачествени тумори
US20030219420A1 (en) Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells
Xie et al. Inhibitory effects of a dendritic cell vaccine loaded with radiation-induced apoptotic tumor cells on tumor cell antigens in mouse bladder cancer
JP5807769B2 (ja) 頭頚部癌の治療に用いる、腫瘍栄養動脈に投与される抗癌細胞組成物の使用
CN116370496B (zh) 胀果甘草多糖在制备治疗和/或预防肝癌的药物中的应用
JP2006124383A (ja) 樹状細胞活性化剤
KR100562274B1 (ko) 수지상 세포를 제조하는 방법 및 상기 수지상 세포를 유효 성분으로 함유하는 약학 조성물
KR102698871B1 (ko) 수지상 세포, 자연 살해 세포 및 세포 독성 t 세포를 포함하는 암의 예방 또는 치료용 생물학적 조성물
WO2009008666A2 (en) Autologous dendritic cell mediated by photodynamic therapy having the ability to suppress the growth of tumor
CN1360025A (zh) 治疗肿瘤的自体免疫细胞及其制备方法
HK1055562B (en) Medicament for the immunotherapy of malignant tumours
CZ22766U1 (cs) Sada pro přípravu protínádorové vakcíny a protinádorová vakcína
EA011421B1 (ru) Способ получения противоопухолевой вакцины